SciSparc Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of October 2023 for SciSparc Ltd., a foreign private issuer headquartered in Tel Aviv, Israel. The filing primarily serves to disseminate a corporate press release regarding a significant intellectual property milestone.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative performance data.
Material Changes
The material event reported is the granting of a patent by the Australian Patent Office for the Company's technology focused on the reduction of opioid use in pain management. No financial changes versus prior periods are disclosed in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the patent grant. The filing does not contain specific financial guidance, outlook projections, or a discussion of risks and contingencies beyond the standard incorporation by reference into existing registration statements.
Key Facts for Investor Verification
- SciSparc Ltd. received a patent from the Australian Patent Office for its pain management technology.
- The technology specifically targets the reduction of opioid use.
- This filing incorporates the press release as Exhibit 99.1 and updates existing registration statements on Forms F-3 and S-8.
- No financial performance data is included in this specific report.